Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Diagnosis & Disease Information
January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
FDA Could Ease Blood Donation Rules for Gay Men
Draft recommendations around the new policy center on ‘individual risk-based questions to reduce the risk of transfusion-transmitted HIV’
FDA Approval Updates Enjaymo Indication for Cold Agglutinin Disease
Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody.
Avapritinib Gets Priority Review for Indolent Systemic Mastocytosis
The sNDA is supported by data from the phase 2 PIONEER trial that evaluated the efficacy and safety of avapritinib in patients with indolent systemic mastocytosis.
Effectiveness of Corticosteroids in Treating Chemotherapy-Induced Thrombocytopenia
Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.
AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Biologic Age Up for Those With Serum Sodium Greater Than 142 mmol/L
Those with middle-age serum sodium >142 mmol/L also have increased risk for developing chronic diseases, premature mortality
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
